|
Re: What is Mr. Market saying about RVX?
|
4
|
Resverlogix Corp.
|
Nov 25, 2018 01:28PM
|
|
Re: What Jardiance/EMPA-REG Outcome means for RVX-208
|
4
|
Resverlogix Corp.
|
Sep 17, 2015 03:35PM
|
|
Re: AHA late breaking abstract
|
4
|
Resverlogix Corp.
|
Nov 10, 2019 02:38PM
|
|
Re: We need news on the status of the Third Eye loan....
|
4
|
Resverlogix Corp.
|
Jan 31, 2019 06:56PM
|
|
Re: Scenario Analysis on end of BETonMACE Phase 3
|
4
|
Resverlogix Corp.
|
Apr 15, 2019 04:09PM
|
|
Re: Pan versus Selective Inhibitors....I need analogies
|
4
|
Resverlogix Corp.
|
Nov 24, 2017 02:59PM
|
|
Re: Warrants
|
4
|
Resverlogix Corp.
|
Jul 31, 2019 05:06PM
|
|
Re: Does anyone here know personally the poster tundup,..?
|
4
|
Resverlogix Corp.
|
Apr 26, 2019 02:42PM
|
|
Re: Broker Meeting 23 Feb
|
4
|
Resverlogix Corp.
|
Mar 01, 2017 12:31PM
|
|
Re: Zenith Abstract at AACR 2017 Meeting April 1-5
|
4
|
Zenith Epigenetics
|
Mar 08, 2017 08:36AM
|
|
Roth coverage
|
4
|
Resverlogix Corp.
|
Oct 29, 2018 11:59AM
|
|
Re: Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
|
4
|
Resverlogix Corp.
|
Apr 18, 2019 09:46AM
|
|
Re: Clarification on BETonMACE baseline data
|
4
|
Resverlogix Corp.
|
Sep 04, 2019 01:07PM
|
|
Re: Resverlogix Confirms Significant Corporate Advancement Establishing Apabetalone as Potential Blockbuster Combo Drug in High-risk Diabetics with CVD
|
4
|
Resverlogix Corp.
|
Jan 13, 2020 08:32AM
|
|
Re: AGM - Jan 7, 2016 - Details
|
4
|
Zenith Epigenetics
|
Jan 08, 2016 01:38PM
|
|
Re: What impact would a PR like this have?
|
4
|
Resverlogix Corp.
|
Jan 30, 2019 07:44AM
|
|
Re: Low Impact Journals
|
4
|
Resverlogix Corp.
|
Apr 15, 2019 04:34PM
|
|
Re: BETonMACE top line data
|
4
|
Resverlogix Corp.
|
Jan 17, 2018 08:53AM
|
|
Re: H1 2020 Potential Events
|
4
|
Resverlogix Corp.
|
Mar 01, 2020 08:59PM
|
|
Resverlogix Zacks SCR Report 6/29/16
|
4
|
Resverlogix Corp.
|
Jun 30, 2016 10:11AM
|
